Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.365 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.76 - 9.6799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 4.365 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
38.76M | 8.89M | - | 3.31M | -8.24M | -0.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marker Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.10 | 4.59 | 4.05 | 4.28 | 10,922 | 0.265 | 6.46% |
1 Month | 4.50 | 4.93 | 4.05 | 4.54 | 19,110 | -0.135 | -3.00% |
3 Months | 4.70 | 4.93 | 3.40 | 4.31 | 18,810 | -0.335 | -7.13% |
6 Months | 2.68 | 6.1568 | 2.40 | 4.44 | 51,252 | 1.69 | 62.87% |
1 Year | 0.9238 | 9.6799 | 0.76 | 2.68 | 262,344 | 3.44 | 372.50% |
3 Years | 23.40 | 36.50 | 0.6706 | 10.50 | 562,555 | -19.04 | -81.35% |
5 Years | 52.40 | 91.70 | 0.6706 | 19.62 | 656,936 | -48.04 | -91.67% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |